Teriflunomide | A77 1726 | Leflunomide Active Metabolite

首页 / / / 脱氢酶 / Teriflunomide

特立氟胺 /Teriflunomide {[allProObj[0].p_purity_real_show]}

货号：A122692 同义名： A77 1726;Flucyamide

Teriflunomide, the active metabolite of an approved antirheumatic drug leflunomide, is an emerging oral therapy for multiple sclerosis (MS). It reversibly inhibits dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines.

Teriflunomide 化学结构
CAS号：163451-81-8

Teriflunomide 3D分子结构
CAS号：163451-81-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Teriflunomide 纯度/质量文件产品仅供科研

货号：A122692 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

脱氢酶亚型比较

产品名称	Dehydrogenase ↓ ↑	纯度
Trilostane	✔	99+%
AGI-6780	+++ IDH2 R140Q mutant, IC50: 23 nM	99%+
Gimeracil	✔	98%
AGI-5198	++ R132H-IDH1, IC50: 70 nM R132C-IDH1, IC50: 0.16 μM	99%+
SW033291	++++ 15-PGDH, IC50: 1.5 nM 15-PGDH, Ki: 0.1 nM	99%+
Mycophenolic acid	✔	99+%
Fomepizole	✔	98%
Leflunomide	✔	98%
3-Nitropropanoic acid	✔	99%+
Isovaleramide	✔	98%
Mycophenolate Mofetil	+++ Inosine monophosphate dehydrogenase I, IC50: 39 nM Inosine monophosphate dehydrogenase II, IC50: 27 nM	98%
MK-8245	++++ SCD1 (rat), IC50: 3 nM SCD1 (mouse), IC50: 1 nM	99%+
Vidofludimus	++ Human DHODH, IC50: 134 nM	99%+
Emodin	✔	98%
Ivosidenib	✔	98%
NCT-501	++ ALDH1A1, IC50: 40 nM	98%
Gossypol	✔	99%+
Devimistat	✔	98%
Disulfiram	✔	98%+
Enasidenib	++++ IDH2, IC50: 12 nM	98%
PluriSIn 1	✔	99%+
ML390	+ DHODH, IC50: 0.56 μM	99%+
Teriflunomide	✔	99%+
Daidzin	+++ ALDH-Ⅰ, Ki: 20 nM	98+%
18β-Glycyrrhetinic acid	✔	99%
RRx-001	✔	95%
NCT-503	+ PHGDH, IC50: 2.5 μM	99%+
Vorasidenib	✔	99%+
Ammonium Glycyrrhizinate(x:1)	✔	98+%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Teriflunomide 生物活性

靶点	Dehydrogenase
描述	Teriflunomide primarily inhibits dihydroorotate dehydrogenase (DHODH), crucial in pyrimidines' de novo synthesis, thereby reducing high-avidity proliferating T and B lymphocytes' activity and potentially moderating autoantigen-induced inflammation in MS, making it more cytostatic than cytotoxic towards leukocytes^[1].
体内研究	Teriflunomide has shown effectiveness in two independent animal models of demyelinating disease, evidenced by its prophylactic and therapeutic benefits in both the dark agouti and female Lewis rat models of experimental autoimmune encephalitis (EAE), highlighting delayed disease onset and reduced symptom severity^[1].
体外研究	Teriflunomide primarily inhibits dihydroorotate dehydrogenase (DHODH), crucial in pyrimidines' de novo synthesis, thereby reducing high-avidity proliferating T and B lymphocytes' activity and potentially moderating autoantigen-induced inflammation in MS, making it more cytostatic than cytotoxic towards leukocytes^[1].

Teriflunomide 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02509052	Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 2019	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 <<
NCT02559765	-		Completed	-	United Kingdom ... 展开 >> The University of Glasgow Glasgow, United Kingdom, G12 8LL 收起 <<
NCT03709446	Breast Neoplasms ... 展开 >> Breast Diseases Metastatic Triple Negative Breast Cancer 收起 <<	Phase 1 Phase 2	Not yet recruiting	October 20, 2021	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai Not yet recruiting New York, New York, United States, 10029 Contact: Charles Shapiro, MD 212-241-3131 charles.shapiro@mssm.edu Contact: Joni Gomes, BSN 212-824-7076 joni.gomes@mssm.edu 收起 <<

Teriflunomide 参考文献

[1]Oh J, et al. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177-90.

Teriflunomide 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

37.01mL

7.40mL

3.70mL

Teriflunomide 技术信息

CAS号	163451-81-8
分子式	C₁₂H₉F₃N₂O₂
分子量	270.207

别名	A77 1726;Flucyamide;SU 20;HMR-1726
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 35 mg/mL(129.53 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02509052	Recurrent Plasma Cell Myeloma ... 展开 >> Refractory Plasma Cell Myeloma 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 2019	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 <<
NCT02559765	-		Completed	-	United Kingdom ... 展开 >> The University of Glasgow Glasgow, United Kingdom, G12 8LL 收起 <<
NCT03709446	Breast Neoplasms ... 展开 >> Breast Diseases Metastatic Triple Negative Breast Cancer 收起 <<	Phase 1 Phase 2	Not yet recruiting	October 20, 2021	United States, New York ... 展开 >> Icahn School of Medicine at Mount Sinai Not yet recruiting New York, New York, United States, 10029 Contact: Charles Shapiro, MD 212-241-3131 charles.shapiro@mssm.edu Contact: Joni Gomes, BSN 212-824-7076 joni.gomes@mssm.edu 收起 <<
NCT02342652	Healthy Elderly Subjects (Age ... 展开 >>≥55 Years) 收起 <<	Phase 1	Completed	-	Singapore ... 展开 >> Singapore, Singapore 收起 <<
NCT03302442	-		Completed	-	France ... 展开 >> Nantes University Hospital Nantes, France, 44093 收起 <<
NCT03535298	Multiple Sclerosis, Relapsing-... 展开 >>Remitting 收起 <<	Phase 4	Not yet recruiting	September 2023	United States, Ohio ... 展开 >> Cleveland Clinic Not yet recruiting Cleveland, Ohio, United States, 44195 Contact: Tammy Skaramagas, BA 216-445-6724 skaramt1@ccf.org Principal Investigator: Daniel Ontaneda, MD, MSc United Kingdom University of Nottingham Not yet recruiting Nottingham, United Kingdom, NG7 2UH Contact: Sara Wilkins +44 115 9249924 ext 66816 Sara.wilkins@nuh.nhs.uk Principal Investigator: Nikos Evangelou, MD, DPhil 收起 <<
NCT03500328	Multiple Sclerosis, Relapsing-... 展开 >>Remitting 收起 <<	Not Applicable	Recruiting	October 31, 2022	-
NCT00273364	Multiple Sclerosis	Phase 2	Active, not recruiting	December 2018	United States, Illinois ... 展开 >> Northwestern University, Feinberg School of Medicine Chicago, Illinois, United States, 60611 收起 <<
NCT02776072	-		Completed	-	-
NCT03399981	-		Active, not recruiting	December 31, 2023	United States, Massachusetts ... 展开 >> Research Site Cambridge, Massachusetts, United States, 02142 收起 <<
NCT02651545	-		Recruiting	November 30, 2020	United States, New York ... 展开 >> Buffalo General Hospital, D3 Recruiting Buffalo, New York, United States, 14203 Contact: Ralph HB Benedict, PhD 716-859-3484 benedict@buffalo.edu 收起 <<
NCT03308994	-		Recruiting	December 31, 2018	France ... 展开 >> Groupement des Hôpitaux de l'Institut Catholique de Lille (HICL) Recruiting Lille, Hauts-de-France, France, 59020 Contact: Arnaud Kwiatkowski, MD-PhD 33320874901 kwiatkowski.arnaud@ghicl.net University Hospital of Lille Recruiting Lille, Hauts-de-France, France, 59037 Contact: Patrick Vermersch, Professor 33320445765 patrick.vermersch@univ-lille2.fr University Hospital Center of Caen Recruiting Caen, Normandie, France, 14033 Contact: Gilles-Louis Defer, Professor 33231064617 defer-gi@chu-caen.fr Contact: Damien Chevanne, PhD 33231064617 chevanne-d@chu-caen.fr University Hospital of Rouen Recruiting Rouen, Normandie, France, 76031 Contact: Bertrand Bourre, MD 33232888990 Bertrand.Bourre@chu-rouen.fr 收起 <<
NCT03122652	Multiple Sclerosis	Phase 3	Recruiting	September 25, 2021	France ... 展开 >> CHU de Bordeaux Recruiting Bordeaux, France, 33000 Contact: Bruno BROCHET, MD Principal Investigator: Bruno BROCHET, MD CHRU de Lille Recruiting Lille, France, 59000 Contact: Patrick VERMERSCH, MD Contact: , MD Principal Investigator: Patrick VERMERSCH Hospices Civils de Lyon Recruiting Lyon, France, 69677 Contact: Sandra VUKUSIC, MD Principal Investigator: Sandra VUKUSIC, MD Sub-Investigator: Françoise DURAND-DUBIEF, MD CHRU de Montpellier Recruiting Montpellier, France, 34000 Contact: Pierre LABAUGE, MD Principal Investigator: Pierre LABAUGE, MD CHU de Nantes Recruiting Nantes, France Contact: Sandrine WIERTLEWSKI Principal Investigator: Sandrine WIERTLEWSKI, MD CHU de Nice Recruiting Nice, France, 06000 Contact: Cassandre LANDES 492034126 ext 33 landes.c@chu-nice.fr Principal Investigator: Christine LEBRUN-FRENAY, MD, PhD CHU de Nîmes Recruiting Nîmes, France Contact: Eric THOUVENOT Principal Investigator: Eric THOUVENOT, MD APHP - Hôpital La Pitié Salpêtrière Recruiting Paris, France, 75013 Contact: Anne-Caroline PAPEIX, MD Principal Investigator: Anne-Caroline PAPEIX, MD Sub-Investigator: Céline LOUAPRE, MD Sub-Investigator: Elisabeth MAILLART, MD CHU de Rennes Recruiting Rennes, France, 35000 Contact: Emmanuelle LE PAGE, MD Principal Investigator: Emmanuelle LE PAGE, MD CHU de Strasbourg Recruiting Strasbourg, France, 67000 Contact: Jérôme DE SEZE, MD Principal Investigator: Jérôme DE SEZE, MD CHU de Toulouse Active, not recruiting Toulouse, France, 31000 Germany University hospital of Charité Not yet recruiting Berlin, Germany Contact: Jens WÜRFEL, MD Principal Investigator: Jens WÜRFEL, MD University Hospital of the Ruhr - University Bochum Not yet recruiting Bochum, Germany, D-44791 Contact: Carsten LUKAS, MD Principal Investigator: Carsten LUKAS, MD University of Heidelberg Not yet recruiting Heidelberg, Germany, 69120 Contact: Brigitte WILDEMANN, MD Principal Investigator: Brigitte WILDEMANN, MD University Medical Center of the Johannes Gutenberg Not yet recruiting Mainz, Germany, 55131 Contact: Frauke ZIPP, MD Principal Investigator: Frauke ZIPP, MD Technische Universität München Not yet recruiting Munich, Germany, 81675 Contact: Mark MÜHLAU, MD Principal Investigator: Mark MÜHLAU, MD Switzerland University Hospital Basel Not yet recruiting Basel, Switzerland, 4031 Contact: Ludwig Kappos, MD Principal Investigator: Ludwig Kappos, MD Turkey Hacettepe University Not yet recruiting Ankara, Turkey Contact: Rana Karabudak, MD Principal Investigator: Rana Karabudak, MD Mustafa Kemal University Active, not recruiting Antakya, Turkey Uludag University School of Medicine Active, not recruiting Bursa, Turkey Istanbul University Active, not recruiting Istanbul, Turkey Kocaeli University School of Medicine Active, not recruiting Kocaeli, Turkey Ondokuz Mayis University, Faculty of Medicine Active, not recruiting Samsun, Turkey United Kingdom Queen's Medical Centre Not yet recruiting Nottingham, United Kingdom Contact: Nikos Evangelou, MD Principal Investigator: Nikos Evangelou, MD 收起 <<
NCT03277248	Relapsing Multiple Sclerosis (... 展开 >>RMS) 收起 <<	Phase 3	Recruiting	September 30, 2021	United States, Arizona ... 展开 >> TG Therapeutics RMS Investigational Trial site Recruiting Phoenix, Arizona, United States, 58018 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Colorado TG Therapeutics RMS Investigational Trial Site Recruiting Aurora, Colorado, United States, 80045 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Florida TG Therapeutics RMS Investigational Trial Site Recruiting Tampa, Florida, United States, 33612 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Kentucky TG Therapeutics RMS Investigational Trial Site Recruiting Lexington, Kentucky, United States, 40513 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Missouri TG Therapeutics RMS Investigational Trial Site Recruiting Chesterfield, Missouri, United States, 63017 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Nevada TG Therapeutics RMS Investigational Trial Site Recruiting Las Vegas, Nevada, United States, 89106 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, New Jersey TG Therapeutics RMS Investigational Trial Site Recruiting Teaneck, New Jersey, United States, 07666 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, New Mexico TG Therapeutics RMS Investigational Trial Site Recruiting Albuquerque, New Mexico, United States, 87131 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, New York TG Therapeutics RMS Investigational Trial Site Recruiting Patchogue, New York, United States, 11772 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Ohio TG Therapeutics RMS Investigational Trial site Recruiting Columbus, Ohio, United States, 43221 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Pennsylvania TG Therapeutics RMS Investigational Trial Site Recruiting Pittsburgh, Pennsylvania, United States, 15212 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Texas TG Therapeutics RMS Investigational Trial site Recruiting San Antonio, Texas, United States, 78258 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com United States, Washington TG Therapeutics RMS Investigational Trial site Recruiting Seattle, Washington, United States, 98122 Contact: TG Therapeutics Clinical Support Team 212-554-4484 RMSclinicalsupport@tgtxinc.com 收起 <<
NCT03768648	Multiple Sclerosis, Relapsing-... 展开 >>Remitting 收起 <<	Not Applicable	Not yet recruiting	January 2019	France ... 展开 >> CHU de Bordeaux - Service de neurologie Not yet recruiting Bordeaux, France Contact: Bruno BROCHET, Prof 05 56 79 55 21 ext +33 bruno.brochet@chu-bordeaux.fr Contact: Mathilde DELOIRE, PhD 05 57 82 12 75 ext +33 mathilde.deloire@chu-bordeaux.fr Principal Investigator: Bruno BROCHET, Prof Sub-Investigator: Aurélie RUET, MD Sub-Investigator: Jean-Christophe OUALLET, MD Sub-Investigator: Cécile DULAU, MD 收起 <<
NCT02679885	-		Recruiting	December 2017	United States, Connecticut ... 展开 >> Multiple Sclerosis Treatment Center at Griffin Hospital Recruiting Derby, Connecticut, United States, 06418 Contact: Joseph Guarnaccia, MD 203-732-1290 mstreatmentcenters@griffinhealth.org 收起 <<
NCT01239459	Renal Impairment	Phase 1	Completed	-	Germany ... 展开 >> Sanofi-Aventis Administrative Office Berlin, Germany 收起 <<
NCT03277261	Relapsing Multiple Sclerosis (... 展开 >>RMS) 收起 <<	Phase 3	Recruiting	September 30, 2021	United States, California ... 展开 >> TG Therapeutics RMS Investigational Trial Site Recruiting Carlsbad, California, United States, 92001 TG Therapeutics RMS Investigational Trial Site Recruiting Long Beach, California, United States, 90808 TG Therapeutics RMS Investigational Trial Site Recruiting Pasadena, California, United States, 91105 TG Therapeutics RMS Investigational Trial Site Recruiting Stanford, California, United States, 94305 United States, Florida TG Therapeutics RMS Investigational Trial Site Recruiting Miami, Florida, United States, 33136 United States, Illinois TG Therapeutics RMS Investigational Trial Site Recruiting Northbrook, Illinois, United States, 60062 United States, Kansas TG Therapeutics RMS Investigational Trial Site Recruiting Kansas City, Kansas, United States, 66160 United States, Michigan TG Therapeutics RMS Investigational Trial Site Recruiting Detroit, Michigan, United States, 48201 United States, New York TG Therapeutics RMS Investigational Trial Site Recruiting Amherst, New York, United States, 14226 United States, Ohio TG Therapeutics RMS Investigational Trial Site Recruiting Westerville, Ohio, United States, 43081 United States, Tennessee TG Therapeutics RMS Investigational Trial Site Recruiting Franklin, Tennessee, United States, 37064 TG Therapeutics RMS Investigational Trial Site Recruiting Knoxville, Tennessee, United States, 37922 United States, Texas TG Therapeutics RMS Investigational Trial Site Recruiting Dallas, Texas, United States, 75246 TG Therapeutics RMS Investigational Site Recruiting Round Rock, Texas, United States, 78681 收起 <<
NCT00811395	Multiple Sclerosis	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Austria Sanofi-Aventis Administrative Office Wien, Austria Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milano, Italy Spain Sanofi-Aventis Administrative Office Barcelona, Spain United Kingdom Sanofi-Aventis Administrative Office Guildford, United Kingdom 收起 <<
NCT01863888	Multiple Sclerosis	Phase 3	Completed	-	Belgium ... 展开 >> Investigational Site Number 056001 Brussels, Belgium, 1070 Investigational Site Number 056002 Overpelt, Belgium, 3900 Investigational Site Number 056003 Sijsele-Damme, Belgium, 8340 Germany Investigational Site Number 276-003 Bad Mergentheim, Germany, 97980 Investigational Site Number 276-004 Hannover, Germany, 30625 Investigational Site Number 276-005 Marburg, Germany, 35043 Investigational Site Number 276-007 Mönchengladbach, Germany, 41061 Investigational Site Number 276-001 Münster, Germany, 48149 Investigational Site Number 276-002 Ulm, Germany, 89073 Netherlands Investigational Site Number 528001 Sittard-Geleen, Netherlands, 6162BG 收起 <<
NCT00811395	-		Completed	-	-
NCT00228163	Multiple Sclerosis	Phase 2	Completed	-	Canada ... 展开 >> Investigational Site Number 16 Calgary, Canada, T2N 2T9 Investigational Site Number 10 Halifax, Canada, B3H 1V7 Investigational Site Number 15 London, Canada, N6A 5A5 Investigational Site Number 12 Montreal, Canada, H2L 4M1 Investigational Site Number 11 Montreal, Canada, H3A 2B4 Investigational Site Number 13 Ottawa, Canada, K1H 8L6 Investigational Site Number 18 Quebec, Canada, G1J 1Z4 Investigational Site Number 14 Toronto, Canada, M5B 1W8 Investigational Site Number 17 Vancouver, Canada, V6T 2B5 Investigational Site Number 19 Winnipeg, Canada, R3E 3N4 France Investigational Site Number 24 Clermont Ferrand Cedex 1, France, 63003 Investigational Site Number 21 Lyon Cedex 03, France, 69394 Investigational Site Number 30 Marseille Cedex 5, France, 13385 Investigational Site Number 23 Montpellier Cedex 5, France, 34000 Investigational Site Number 28 Nice Cedex, France, 06002 Investigational Site Number 27 Rennes Cedex, France, 35033 收起 <<
NCT02833714	-		Terminated	-	United States, North Carolina ... 展开 >> University of North Carolina Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT02425644	Multiple Sclerosis	Phase 3	Active, not recruiting	May 15, 2019	-
NCT01881191	-		Completed	-	United States, New York ... 展开 >> Buffalo Neuroimaging Analysis Center Buffalo, New York, United States, 14203 收起 <<
NCT03368677	-		Recruiting	November 2024	Finland ... 展开 >> Turku PET Centre Recruiting Turku, Finland Proper, Finland, 20520 Contact: Laura Airas, MD,professor 023130000 laura.airas@utu.fi 收起 <<
NCT00883337	Multiple Sclerosis	Phase 3	Completed	-	-
NCT01403376	-		Completed	-	-
NCT01403376	Multiple Sclerosis	Phase 2	Completed	-	Austria ... 展开 >> Investigational Site Number 040001 Wien, Austria, 1010 Canada Investigational Site Number 124005 Calgary, Canada, T2N 2T9 Investigational Site Number 124003 Greenfield Park, Canada, J4V 2J2 Investigational Site Number 124002 London, Canada, N6A 5A5 Investigational Site Number 124007 Montreal, Canada, H3A 2B4 Investigational Site Number 124008 Ottawa, Canada, K1H 8L6 Investigational Site Number 124001 Quebec, Canada, G1J 1Z4 Investigational Site Number 124009 Toronto, Canada, M5B 1W8 Germany Investigational Site Number 276003 Berlin, Germany, 10785 Investigational Site Number 276001 Essen, Germany, 45122 Investigational Site Number 276002 Münster, Germany, 48149 Russian Federation Investigational Site Number 643002 Nizhny Novgorod, Russian Federation, 603076 Ukraine Investigational Site Number 804002 Ivano-Frankovsk, Ukraine, 76008 Investigational Site Number 804001 Kharkiv, Ukraine, 61018 收起 <<
NCT00475865	Multiple Sclerosis	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Austria Sanofi-Aventis Administrative Office Vienna, Austria Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milan, Italy United Kingdom Sanofi-Aventis Administrative Office Guildford, United Kingdom 收起 <<
NCT00751881	Multiple Sclerosis	Phase 3	Completed	-	-
NCT00803049	Multiple Sclerosis	Phase 3	Completed	-	-
NCT00489489	Multiple Sclerosis	Phase 2	Completed	-	United States, New Jersey ... 展开 >> Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States, 08807 Canada Sanofi-Aventis Administrative Office Laval, Canada Germany Sanofi-Aventis Administrative Office Berlin, Germany Italy Sanofi-Aventis Administrative Office Milan, Italy Spain Sanofi-Aventis Administrative Office Barcelona, Spain 收起 <<
NCT00883337	-		Completed	-	-
NCT00751881	-		Completed	-	-
NCT00134563	Multiple Sclerosis	Phase 3	Completed	-	-
NCT00475865	-		Completed	-	-
NCT00803049	-		Completed	-	-
NCT01252355	-		Terminated(Sponsor decision to... 展开 >> prematurely stop the study, not linked to any safety concern.) 收起 <<	-	-
NCT02587195	Multiple Sclerosis	Phase 3	Active, not recruiting	January 18, 2019	France ... 展开 >> CHU de Besançon Besançon, France, 25030 CHU de Lille Lille, France, 59037 CHU de Montpellier Montpellier, France, 34295 CHU de Nice Nice, France, 06000 CHU de Strasbourg Strasbourg, France, 67098 收起 <<
NCT00134563	-		Completed	-	-
NCT00622700	Multiple Sclerosis	Phase 3	Completed	-	-
NCT01252355	Multiple Sclerosis Relapse	Phase 3	Terminated(Sponsor decision to... 展开 >> prematurely stop the study, not linked to any safety concern.) 收起 <<	-	-
NCT00489489	-		Completed	-	-
NCT02792231	Relapsing Multiple Scelrosis	Phase 3	Recruiting	May 15, 2019	-
NCT02792218	Relapsing Multiple Sclerosis	Phase 3	Active, not recruiting	May 16, 2019	-
NCT02046629	Multiple Sclerosis	Phase 1	Completed	-	China ... 展开 >> Investigational Site Number 156001 Shanghai, China, 200025 收起 <<
NCT02201108	Multiple Sclerosis	Phase 3	Active, not recruiting	September 2021	-
NCT03198351	-		Recruiting	February 1, 2022	United States, California ... 展开 >> Investigator Recruiting San Diego, California, United States, 92093 收起 <<
NCT00622700	-		Completed	-	-
NCT01895335	Multiple Sclerosis	Phase 4	Completed	-	-
NCT01487096	Multiple Sclerosis	Phase 2	Completed	-	Canada, Ontario ... 展开 >> Canada Toronto, Ontario, Canada France sanofi-aventis France Lyon, France 收起 <<
NCT01895335	-		Completed	-	-
NCT03464448	-		Recruiting	October 2021	United States, Michigan ... 展开 >> University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Principal Investigator: Yang Mao-Draayer, MD/PHD 收起 <<
NCT02490982	-		Enrolling by invitation	December 2019	Canada, Quebec ... 展开 >> CHUM Montréal, Quebec, Canada, H2L 4M1 收起 <<
NCT01970410	Multiple Sclerosis	Phase 4	Active, not recruiting	June 2018	United States, Arizona ... 展开 >> Phoenix Neurological Associates, Ltd Phoenix, Arizona, United States, 85018 United States, New York Multiple Sclerosis Center of Northeastern New York Latham, New York, United States, 12110 United States, Oregon Providence Multiple Sclerosis Center Portland, Oregon, United States, 97225 收起 <<
NCT02263547	Teriflunomide Elimination ... 展开 >> Healthy Volunteers 收起 <<	Phase 1	Terminated(PK time points were... 展开 >> not being met as expected. Determination that risks outweighed benefit.) 收起 <<	-	United States, Florida ... 展开 >> USF Carol and Frank Morsani Center for Advanced Healthcare Tampa, Florida, United States, 33612 收起 <<
NCT03561402	-		Recruiting	February 28, 2019	Canada, Quebec ... 展开 >> Department of Pathology Recruiting Montréal, Quebec, Canada, H3A 2B4 Contact: David Haegert, MD 收起 <<
NCT03526224	-		Active, not recruiting	November 2019	United States, New York ... 展开 >> Buffalo Neuroimaging Analysis Center Buffalo, New York, United States, 14203 收起 <<

特立氟胺 /Teriflunomide {[allProObj[0].p_purity_real_show]}

Teriflunomide 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Teriflunomide 质控信息

Teriflunomide 生物活性

Teriflunomide 临床研究

Teriflunomide 参考文献

Teriflunomide 实验方案

Teriflunomide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

特立氟胺 /Teriflunomide {[allProObj[0].p_purity_real_show]}

Teriflunomide 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Teriflunomide 质控信息

Teriflunomide 生物活性

Teriflunomide 临床研究

Teriflunomide 参考文献

Teriflunomide 实验方案

Teriflunomide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Teriflunomide 纯度/质量文件产品仅供科研